We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+9.6%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$21.1M
Cap. Flow
-$6.89M
Cap. Flow %
-6.4%
Top 10 Hldgs %
79.92%
Holding
31
New
4
Increased
4
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$8.69M
2
ATRS
Antares Pharma, Inc.
ATRS
+$4.89M
3
OPTN
OptiNose
OPTN
+$4.76M
4
TELA icon
TELA Bio
TELA
+$1.83M
5
VTRS icon
Viatris
VTRS
+$1.32M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$11.3M
2
NMTR
9 Meters Biopharma
NMTR
+$4.24M
3
LITS
Lite Strategy Inc
LITS
+$2M
4
CRIS icon
Curis
CRIS
+$1.19M
5
NKGN
NKGen Biotech, Inc. Common Stock
NKGN
+$836K

Sector Composition

Rank Sector Weight
1 Healthcare 85.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LNTH icon
1
Lantheus
LNTH
$6.59B
$17.7M 16.42%
320,000
-301,753
-49% -$11.3M
RDUS
2
DELISTED
Radius Health, Inc.
RDUS
$12.6M 11.65%
1,421,500
+1,146,219
+416% +$8.69M
ADMA icon
3
ADMA Biologics
ADMA
$2.18B
$10.7M 9.89%
5,822,798
+425,000
+8% +$663K
JSPR icon
4
Jasper Therapeutics
JSPR
$26.6M
$10.2M 9.45%
321,904
– –
IMCR icon
5
Immunocore
IMCR
$1.73B
$8.77M 8.14%
293,385
– –
SNCE
6
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$6.27M 5.82%
58,633
-1,367
-2% -$214K
ATRS
7
DELISTED
Antares Pharma, Inc.
ATRS
$5.52M 5.13%
+1,346,971
New +$4.89M
TELA icon
8
TELA Bio
TELA
$41.6M
$5.25M 4.87%
451,400
+151,400
+50% +$1.83M
OPTN
9
DELISTED
OptiNose
OPTN
$4.94M 4.58%
+133,333
New +$4.76M
STLN
10
Starling Oncology, Inc. Common Stock
STLN
$616M
$4.28M 3.97%
600,000
– –
NYXH
11
Nyxoah
NYXH
$158M
$3.12M 2.89%
162,966
-14,713
-8% -$296K
CFMS
12
DELISTED
Conformis, Inc. Common Stock
CFMS
$2.9M 2.69%
185,780
+19,116
+11% +$314K
SNDA icon
13
Sonida Senior Living
SNDA
$1.99B
$2.74M 2.55%
82,832
– –
RAPT
14
DELISTED
RAPT Therapeutics
RAPT
$2.42M 2.24%
13,750
– –
HCSG icon
15
Healthcare Services Group
HCSG
$1.5B
$2.28M 2.12%
123,000
– –
CRBU icon
16
Caribou Biosciences
CRBU
$165M
$1.93M 1.79%
210,695
– –
SLGC
17
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$1.89M 1.75%
235,300
– –
CMRX
18
DELISTED
Chimerix, Inc.
CMRX
$1.83M 1.7%
400,000
– –
VTRS icon
19
Viatris
VTRS
$18.7B
$1.09M 1.01%
+100,000
New +$1.32M
RZLT icon
20
Rezolute
RZLT
$451M
$1.01M 0.94%
300,000
– –
TSVT
21
DELISTED
2seventy bio
TSVT
$404K 0.37%
+23,657
New +$401K
NKGNW
22
DELISTED
NKGen Biotech, Inc. Warrants
NKGNW
$11K 0.01%
20,000
– –
SLGCW
23
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$4K ﹤0.01%
2,060
– –
BBIO icon
24
BridgeBio Pharma
BBIO
$16.6B
– –
-1,125
Closed -$19K
CRIS icon
25
Curis
CRIS
$7.13M
– –
-625
Closed -$1.19M
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return

Velan Capital Investment Management's Q1 2022 Portfolio in Review

As of Q1 2022, Velan Capital Investment Management held 31 positions worth $108M, down 16% from $129M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Velan Capital Investment Management withdrew a net $6.89M in Q1 2022, closing 8 positions and reducing 3 holdings. Its most notable exit was 9 Meters Biopharma, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in Antares Pharma, Inc. worth $5.52M.

  • Velan Capital Investment Management's largest Q1 2022 buy was Antares Pharma, Inc.: 1,346,971 shares worth $5.52M.
  • Velan Capital Investment Management added most to Radius Health, Inc. in Q1 2022, an estimated $8.69M increase.
  • Velan Capital Investment Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $11.3M.
  • Velan Capital Investment Management fully exited 9 Meters Biopharma in Q1 2022, selling an estimated $4.24M.
  • Velan Capital Investment Management's ten largest holdings make up 80% of its $108M portfolio in Q1 2022.
  • Velan Capital Investment Management opened 4 new positions and closed 8 in Q1 2022.
  • Velan Capital Investment Management's portfolio value fell 16% quarter-over-quarter to $108M.

Based on Velan Capital Investment Management's 13F filing for Q1 2022, filed 16 May 2022.